149017-66-3
Chemical Structure
PPADS
- CAS No.: 149017-66-3
- Formula:C14H14N3O12PS2
- Molecular Weight:511.38
IUPAC Name: (E)-4-((4-formyl-5-hydroxy-6-methyl-3-((phosphonooxy)methyl)pyridin-2-yl)diazenyl)benzene-1,3-disulfonic acid
InChIKey: PNFZSRRRZNXSMF-WUKNDPDISA-N
SMILES: O=CC1=C(C(C)=NC(/N=N/C2=CC=C(S(=O)(O)=O)C=C2S(=O)(O)=O)=C1COP(O)(O)=O)O
Biological Activity: PPADS is a P2X receptor (P2X Receptor) antagonist and a reversible competitive antagonist of NAADP receptors, with IC50 values of 68 nM (P2X1) and 214 nM (P2X3), respectively. PPADS alleviates pain-related behaviors in the central and peripheral nervous systems of mice after peripheral neuropathy, inhibits the overproduction of IL-1β, IL-6, iNOS and nNOS, and suppresses the hydrolytic activity of extracellular ATPase. PPADS blocks ATP-mediated inward currents on recombinant rat P2X1 and P2X3 receptors, and inhibits purinergic nerve stimulation-induced contraction of rabbit bladder detrusor muscle. PPADS is applicable to research related to neuropathic pain[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PPADS | PPADS is a P2X receptor (P2X Receptor) antagonist and a reversible competitive antagonist of NAADP receptors, with IC50 values of 68 nM (P2X1) and 214 nM (P2X3), respectively. PPADS alleviates pain-related behaviors in the central and peripheral nervous systems of mice after peripheral neuropathy, inhibits the overproduction of IL-1β, IL-6, iNOS and nNOS, and suppresses the hydrolytic activity of extracellular ATPase. PPADS blocks ATP-mediated inward currents on recombinant rat P2X1 and P2X3 receptors, and inhibits purinergic nerve stimulation-induced contraction of rabbit bladder detrusor muscle. PPADS is applicable to research related to neuropathic pain. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Martucci C, et al. The purinergic antagonist PPADS reduces pain related behaviours and interleukin-1 beta, interleukin-6, iNOS and nNOS overproduction in central and peripheral nervous system after peripheral neuropathy in mice. Pain. 2008;137(1):81-95. [Content Brief]
- [2]. Billington RA, et al. PPADS is a reversible competitive antagonist of the NAADP receptor. Cell Calcium. 2007;41(6):505-511. [Content Brief]
- [3]. Brown SG, et al. Actions of a Series of PPADS Analogs at P2X1 and P2X3 Receptors. Drug Dev Res. 2001 Aug;53(4):281-291. [Content Brief]
- [4]. Ziganshin AU, et al. PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder. Br J Pharmacol. 1993;110(4):1491-1495. [Content Brief]
Keywords
